Abbott Labs: A Boring Dividend Machine That Could Quietly Make You Rich

Abbott Laboratories' business, if not exciting, is resilient and consistent. The company is a leader in multiple markets and has attractive growth avenues.

The Motley Fool • Feb 23, 2026

Abbott (ABT) Reports Q4 Earnings: What Key Metrics Have to Say

While the top- and bottom-line numbers for Abbott (ABT) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zacks Investment Research • Feb 23, 2026

Abbott (ABT) Ascends While Market Falls: Some Facts to Note

Abbott (ABT) reached $115.29 at the closing of the latest trading day, reflecting a +2.74% change compared to its last close.

Zacks Investment Research • Feb 23, 2026

Abbott declares 409th consecutive quarterly dividend

ABBOTT PARK, Ill., Feb. 20, 2026 /PRNewswire/ -- The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 63 cents per share.

PRNewsWire • Feb 20, 2026

Exact Sciences Stockholders Approve Acquisition by Abbott

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corporation (NASDAQ: EXAS) (“Exact Sciences”), a leading provider of cancer screening and diagnostic tests, today announced that its stockholders voted to approve the proposed acquisition of Exact Sciences by Abbott (NYSE: ABT) at the special meeting of stockholders held earlier today. At the special meeting, preliminary results showed that more than 99% of the votes cast, representing approximately 67% of the total outstanding shares of Exact Scie.

Business Wire • Feb 20, 2026

BSX vs. ABT: Which MedTech Stock is the Better Investment Now?

Abbott edges out Boston Scientific in the MedTech faceoff, with valuation appeal, strong CGM momentum and strategic deals boosting its investment case.

Zacks Investment Research • Feb 20, 2026

Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It

Abbott (ABT) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Zacks Investment Research • Feb 18, 2026

Carl Abbott's “House of Columns” Brings Sarasota School Modernism to the Market on Longboat Key

LISTING LINK: https://www.premiersothebysrealty.com/single-family/mfr/a4681242/6610-gulf-of-mexico-drive-longboat-key-fl-34228 DROPBOX: https://tours.coastalhomephotography.net/public/vtour/display/2359971?idx=1#!/nav/gallery PHOTO CREDIT: Coastal Home Photography LONGBOAT KEY, Fla.

GlobeNewsWire • Feb 17, 2026

Baron Discovery Fund Q4 2025: Winners, Laggards, Buys & Sells

In the fourth quarter of 2025, the Baron Discovery Fund returned 0.19% (Institutional Shares), trailing the Russell 2000 Growth Index by 1.03%. In these periods, low quality (high debt and poor profitability) and short-term price momentum-oriented stocks outperformed. Exact Sciences Corporation received a buyout offer in the fourth quarter by Abbott Laboratories (ABT) for a price of $105 in cash.

Seeking Alpha • Feb 15, 2026

Abbott Labs Just Extended Its Dividend Aristocrat Status: What Comes Next?

Abbott Laboratories just paid its quarterly dividend of $0.63 per share on February 13, 2026, marking a 6.8% increase from the prior quarterly rate.

24/7 Wall Street • Feb 12, 2026